<DOC>
	<DOC>NCT02653599</DOC>
	<brief_summary>This trial is a multi-center, randomized, double-blind, placebo-controlled parallel group, Phase 2 study in subjects with Type 2 diabetes mellitus on a stable dose of metformin to evaluate the safety and efficacy of TTP273 versus placebo glucose control and body weight following administration for 3 months.</brief_summary>
	<brief_title>A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>The subject has a 6 month diagnosis of Type 2 diabetes mellitus prior to screening and meets the American Diabetes Association (ADA) guidelines for Type 2 diabetes mellitus. On a stable regimen of metformin monotherapy equivalent to at least 1000 mg/day for the last 3 months prior to screening. Males. Females of nonchildbearing potential. Generally stable health without a history of major surgery or significant injuries within the last year and without an active infection. Diagnosis of Type 1 diabetes mellitus, maturityonset diabetes of the young, insulinrequiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus, or history of diabetic ketoacidosis. Participation in a clinical trial and receipt of an investigational product within 30 days. Participation in any formal weight loss program, or fluctuation of &gt; 5% in body weight, or having received medications approved for weight loss within 3 months prior to screening or contemplating such therapy during the trial. Previous surgical treatment of obesity. Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice administered by someone other than the patient within 6 months prior to screening. Use of other diabetic agents except metformin within 3 months prior to Screening. History of pancreatitis. Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to screening. History of hemolytic anemia, chronic transfusion requirement or other condition rendering HbA1c results unreliable. History of MEN2 or family history of medullary thyroid cancer. History or presence of clinically significant disease (other than Type 2 diabetes mellitus).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>